NewsRoom Articles - Page 52 of 220

WednesdayFeb 21, 2024 12:00 pm

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies Sigyn Therapeutics (OTCQB: SIGYD,…

WednesdayFeb 21, 2024 10:00 am

FDA Grants Florida Permission to Import More Affordable Medicines from Canada

The FDA recently approved a plan that permits the state of Florida to import some drugs from Canada at lower prices than the medications that can be acquired in America. It is a well-known fact that the cost of drugs in the United States is high, with numerous studies finding that in comparison to other developed countries, America spends significantly more on prescription medications. One analysis by the Government Accountability Office determined that the prices of most prescribed medications were almost three times higher in America than in Canada. Various factors help determine the exact amount every patient pays for…

TuesdayFeb 20, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions The prevalence of autism spectrum disorder (“ASD”) in the United…

FridayFeb 16, 2024 9:45 am

Study Links Microbiome Composition to Autism Spectrum Disorder

Israeli researchers have discovered a potential link between microbiome composition and autism spectrum disorder (ASD). Autism is a neurodevelopmental condition that causes repetitive behaviors and decreased social communication in affected individuals. Scientists have spent the past few decades trying to learn about the underlying mechanisms that trigger the condition and its symptoms. Although research shows that cases of autism spectrum disorder are on the rise, scientists still don’t understand what causes the neurodevelopmental disorder. Some posit that rare gene mutations or changes coupled with small genetic variations in ASD patients may be responsible for causing the condition. Researchers from Bar-Ilan…

WednesdayFeb 14, 2024 10:00 am

Study Links Ramadan Fasting to Lower Risk of Chronic Disease Development

A recent study has revealed that Ramadan fasting may be associated with a lower risk of developing chronic diseases. Published in the “American Journal of Clinical Nutrition,” the study found that Ramadan fasting was linked with a significant reduction in the risk of breast, colorectal and lung cancers. Researchers collected data from 72 participants from the London Ramadan Study (LORANS), an observational cohort of 140 Muslims who follow the annual Ramadan fast. Ramadan typically involves avoiding all food and drink from before the day’s first light till the sun sets on a specific set of days every year. The researchers…

TuesdayFeb 13, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking…

MondayFeb 12, 2024 9:45 am

New MRI Procedure Eases Multiple Sclerosis Diagnosis

Researchers from ETH Zurich have developed a new magnetic resonance imaging (MRI) technique that can ease multiple sclerosis diagnosis and produce more accurate findings. Led by Emily Baadsvik and Markus Weiger from ETH Zurich’s Institute for Biomedical Engineering, the research team created a technique to map myelin sheath conditions for more accurate diagnoses. Multiple sclerosis (MS) is a potentially disabling neurological condition that affects the central nervous system (brain and spinal cord). It occurs when the immune system becomes dysfunctional and starts to attack myelin, the protective sheath that covers and protects nerve fibers, resulting in communication problems between the…

FridayFeb 09, 2024 11:00 am

The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases

Estimates from the United Nations show that about 363 million individuals worldwide are affected by humanitarian crises driven by the climate crisis, increase conflict and fragility, and broadening inequality. In 2022, more than 108 million individuals were forced to flee their homes due to conflict. While humanitarian crises such as those currently occurring in Gaza, Sudan, Libya, Somalia and Ukraine may vary in scale and nature, they all share infrastructure demolition, displacement of the masses, and the disruption of services and supply chains. Healthcare facilities are also heavily impacted in times of conflict, particularly because they are directly targeted. Access…

WednesdayFeb 07, 2024 10:15 am

Patients with Swelling Disorder See New Gene Therapy as Godsend

A new gene therapy is transforming the lives of patients with a debilitating hereditary condition that causes painful and even fatal levels of swelling. The therapy led to significantly promising results in its first trial involving humans, with patients involved in the study reporting “dramatic improvements” in their symptoms that allowed them to stop taking long-term medication and resume their regular day-to-day activities. Hereditary angioedema is a rare condition that arises from a genetic mutation and causes leaky blood vessels in patients. This leads to random bouts of swelling that can affect the hand, feet, throat, bowels, mouth and lips…

WednesdayFeb 07, 2024 9:00 am

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023 The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients Historical results from outside…